Literature DB >> 11920233

Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma.

R Burger1, A Guenther, F Bakker, M Schmalzing, S Bernand, W Baum, B Duerr, G M Hocke, H Steininger, E Gebhart, M Gramatzki.   

Abstract

INTRODUCTION: Cytokines of the gp130-family, particularly interleukin(IL)-6, play a crucial role in the propagation of malignant plasma cells.
MATERIALS AND METHODS: The role of IL-6 and other gp130-cytokines was studied in the human plasma cell line INA-6 in vitro and in INA-6 xenografts. The proliferative response to gp130-cytokines was evaluated and activated components of gp130-signaling pathways were identified by Western blotting and DNA binding studies. Specifically, expression of IL-6 and receptors for IL-6 and leukemia inhibitory factor were analysed by RT-PCR and ELISA.
RESULTS: The plasma cell line INA-6 was cultured for several years remaining strictly dependent on exogenous IL-6. Other gp130-cytokines had no significant effect on INA-6 cell proliferation in vitro. Due to an activating mutation in the N-ras gene, mitogen-activated protein kinases (MAPK) were constitutively phosphorylated. In contrast, signal transducer and activator of transcription(STAT)-3 activation was dependent on stimulation with IL-6. Blocking of either one of these pathways resulted in a significant decrease of INA-6 cell proliferation. Remarkably, INA-6 xenografts did not require exogeneous IL-6 for proliferation in vivo. Instead, an autocrine IL-6 loop and, in certain tumor sublines, responsiveness to additional gp130-cytokines was induced during in vivo growth.
CONCLUSION: Activation of the gp130 signal transducer is mandatory for INA-6 cell growth in vitro and in vivo. Both the MAPK and the Jak/STAT pathway are operative in malignant plasma cells and either one is essential for plasma cell growth. The INA-6 cell line provides a preclinical model to study growth regulation of human plasmacytoma cells and to evaluate novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11920233     DOI: 10.1038/sj.thj.6200075

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  45 in total

1.  Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

Authors:  Dharminder Chauhan; Madhavi Bandi; Ajita V Singh; Arghya Ray; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2011-09-26       Impact factor: 6.998

2.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Authors:  Kihyun Kim; Sun-Young Kong; Mariateresa Fulciniti; Xianfeng Li; Weihua Song; Sabikun Nahar; Peter Burger; Mathew J Rumizen; Klaus Podar; Dharminder Chauhan; Teru Hideshima; Nikhil C Munshi; Paul Richardson; Ann Clark; Janet Ogden; Andreas Goutopoulos; Luca Rastelli; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Br J Haematol       Date:  2010-03-12       Impact factor: 6.998

3.  MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Authors:  Sonia Vallet; Noopur Raje; Kenji Ishitsuka; Teru Hideshima; Klaus Podar; Shweta Chhetri; Samantha Pozzi; Iris Breitkreutz; Tanyel Kiziltepe; Hiroshi Yasui; Enrique M Ocio; Norihiko Shiraishi; Janice Jin; Yutaka Okawa; Hiroshi Ikeda; Siddhartha Mukherjee; Nileshwari Vaghela; Diana Cirstea; Marco Ladetto; Mario Boccadoro; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

4.  A clinically relevant SCID-hu in vivo model of human multiple myeloma.

Authors:  Pierfrancesco Tassone; Paola Neri; Daniel R Carrasco; Renate Burger; Victor S Goldmacher; Robert Fram; Vidit Munshi; Masood A Shammas; Laurence Catley; Gary S Jacob; Salvatore Venuta; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

5.  Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Authors:  Jagadish Kummetha Venkata; Ningfei An; Robert Stuart; Luciano J Costa; Houjian Cai; Woodrow Coker; Jin H Song; Kiwana Gibbs; Terri Matson; Elizabeth Garrett-Mayer; Zhuang Wan; Besim Ogretmen; Charles Smith; Yubin Kang
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

6.  Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.

Authors:  W Grady Gunn; Ulf Krause; Narae Lee; Carl A Gregory
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

7.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

8.  Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.

Authors:  Dharminder Chauhan; Ajita V Singh; Bryan Ciccarelli; Paul G Richardson; Michael A Palladino; Kenneth C Anderson
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

9.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

10.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.